TVTX

56.93

0.14% 0.08

Dopo l'orario di chiusura: 56.93

Travere Therapeutics Inc (TVTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TVTX Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$56.85

Aprire:

$57.21

Volume 24 ore:

1.74M

Relative Volume:

1.14

Capitalizzazione di mercato:

$5.37B

Reddito:

$536.20M

Utile/perdita netta:

$-45.64M

Rapporto P/E:

-106.45

EPS:

-0.5348

Flusso di cassa netto:

$-28.94M

1 W Prestazione:

-4.22%

1M Prestazione:

-15.32%

6M Prestazione:

+87.02%

1 anno Prestazione:

+135.05%

Intervallo 1D:

$56.34

$57.53

Intervallo di 1 settimana:

$56.23

$61.87

Portata 52W:

$22.59

$68.73

Travere Therapeutics Inc Stock (TVTX) Company Profile

Nome

Travere Therapeutics Inc

Settore

Healthcare (1064)

Industria

Biotechnology (595)

Telefono

888-969-7879

Indirizzo

3611 VALLEY CENTRE DR, SAN DIEGO

Dipendente

497

Cinguettio

Prossima data di guadagno

2026-10-29

Ultimi documenti SEC

TVTX's Discussions on Twitter

Compare TVTX vs VRTX, MRNA, REGN, ARGX, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TVTX Travere Therapeutics Inc	56.93	5.60B	536.20M	-45.64M	-28.94M	-0.5348
VRTX Vertex Pharmaceuticals Inc	504.73	133.37B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-14	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-10-31	Reiterato	Citigroup	Buy
2025-06-11	Reiterato	Citigroup	Buy
2025-06-11	Ripresa	H.C. Wainwright	Buy
2025-01-10	Iniziato	Cantor Fitzgerald	Overweight
2024-10-21	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-09-09	Aggiornamento	Guggenheim	Neutral → Buy
2024-03-27	Downgrade	Guggenheim	Buy → Neutral
2023-12-05	Aggiornamento	Citigroup	Neutral → Buy
2023-11-20	Iniziato	Citigroup	Neutral
2023-09-22	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-09-21	Downgrade	William Blair	Outperform → Mkt Perform
2023-09-06	Ripresa	Evercore ISI	Outperform
2023-07-21	Iniziato	JP Morgan	Overweight
2023-06-07	Ripresa	Piper Sandler	Neutral
2023-05-22	Iniziato	TD Cowen	Outperform
2023-05-05	Aggiornamento	Bryan Garnier	Sell → Neutral
2023-03-01	Iniziato	Guggenheim	Buy
2023-02-21	Aggiornamento	Wedbush	Neutral → Outperform
2022-12-14	Iniziato	Stifel	Hold
2022-12-05	Iniziato	Wells Fargo	Overweight
2022-09-21	Iniziato	Bryan Garnier	Sell
2022-07-14	Ripresa	Canaccord Genuity	Buy
2022-03-31	Iniziato	Piper Sandler	Overweight
2022-02-28	Iniziato	H.C. Wainwright	Buy
2021-05-26	Downgrade	Wedbush	Outperform → Neutral

Mostra tutto

Travere Therapeutics Inc Borsa (TVTX) Ultime notizie

Sep 30, 2026

Investigation launched into Travere Therapeutics officers for possible self-dealing harming shareholders - Pluang

Sep 30, 2026

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm - TradingView

Sep 30, 2026

Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain? - Simply Wall Street

Sep 30, 2026

Sep 25, 2026

Guggenheim raises Travere Therapeutics stock price target on patent By Investing.com - Investing.com Canada

Sep 24, 2026

Sep 23, 2026

Understanding the Setup: (TVTX) and Scalable Risk - news.stocktradersdaily.com

Sep 23, 2026

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI - marketscreener.com

Sep 23, 2026

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis - BioSpace

Sep 23, 2026

Travere receives patent allowance for FILSPARI use in FSGS - Investing.com

Sep 23, 2026

Travere TherapeuticsReceives USPTO Notice Of Allowance For Filspari Patent In FSGS - TradingView

Sep 23, 2026

Sep 22, 2026

TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits

Sep 22, 2026